Nuvalent Inc (NUVL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Nuvalent Inc stock (NUVL) is currently trading at $98.00. Analyst consensus price target for NUVL is $143.94. WallStSmart rates NUVL as Sell.
- NUVL PE ratio analysis and historical PE chart
- NUVL PS ratio (Price-to-Sales) history and trend
- NUVL intrinsic value — DCF, Graham Number, EPV models
- NUVL stock price prediction 2025 2026 2027 2028 2029 2030
- NUVL fair value vs current price
- NUVL insider transactions and insider buying
- Is NUVL undervalued or overvalued?
- Nuvalent Inc financial analysis — revenue, earnings, cash flow
- NUVL Piotroski F-Score and Altman Z-Score
- NUVL analyst price target and Smart Rating
Nuvalent Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Nuvalent Inc (NUVL) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and price/book. Significant fundamental concerns warrant caution or avoidance.
Nuvalent Inc (NUVL) Key Strengths (2)
111.41% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Nuvalent Inc (NUVL) Areas to Watch (2)
Company is destroying shareholder value
Very expensive at 6.0x book value
Nuvalent Inc (NUVL) Detailed Analysis Report
Overall Assessment
This company scores 15/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 2 register as strengths (avg 8.5/10) while 2 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Price/Book. Some valuation metrics including Price/Book (5.98) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -36.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -36.70% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NUVL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Nuvalent Inc (NUVL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Nuvalent Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -73M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Nuvalent Inc.
Bottom Line
Nuvalent Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Nuvalent Inc(NUVL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Nuvalent Inc. is a pioneering clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, the company aims to create innovative treatments that specifically target genetic mutations responsible for tumor growth, thereby improving patient outcomes and minimizing side effects. With a robust pipeline of highly selective therapies, Nuvalent is strategically positioned within the precision oncology market, making it well-equipped to seize emerging opportunities in the rapidly evolving biotechnology sector. The company’s relentless commitment to advancing cancer treatment underscores its potential to significantly impact patient care in oncology.